Managing non-alcoholic fatty liver disease in diabetes: challenges and opportunities [PDF]
, 2017 Non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus are two common health problems worldwide. Globally, it has been estimated that a quarter of the adult population in the world currently suffers from NAFLD.1 In Asia, probably ...
Lam, KSL, Lee, CHP
core +1 more source
Rethinking the bile acid/gut microbiome axis in cancer [PDF]
, 2017 Dietary factors, probiotic agents, aging and antibiotics/medicines impact on gut microbiome composition leading to disturbances in localised microbial populations.
Caparros-Martin, Jose A. +4 more
core +1 more source
Obeticholic acid—a new therapy in PBC and NASH [PDF]
British Medical Bulletin, 2020 Abstract Introduction Obeticholic acid (OCA) is a semi-synthetic hydrophobic bile acid (BA) analogue that is highly selective agonist of farnesoid X receptor (FXR), a key nuclear BA receptor, which induces expression of gut-derived hormones, in particular fibroblast growth factor 19.
Roger W Chapman, Kate D Lynch
openaire +2 more sources
The role of lipid and lipoprotein metabolism in non-alcoholic fatty liver disease [PDF]
, 2017 Due to the epidemic of obesity across the world, nonalcoholic fatty liver disease (NAFLD) has become one of the most prevalent chronic liver disorders in children and adolescents.
Anania, Caterina +4 more
core +2 more sources
Evolving Role for Pharmacotherapy in NAFLD/NASH
Clinical and Translational Science, 2021 Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent, dynamic disease that occurs across the age spectrum and can lead to cirrhosis and hepatocellular carcinoma.
Suzanna L. Attia +2 more
doaj +1 more source
Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway [PDF]
, 2015 The prevalence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) is increasing world-wide in parallel to the increase of the obesity epidemic.
Filozof, Claudia +3 more
core +2 more sources
New treatments/targets for primary biliary cholangitis
JHEP Reports, 2019 Summary: Primary biliary cholangitis (PBC) is an autoimmune, cholestatic, chronic liver disease that ultimately progresses towards cirrhosis and liver failure if untreated.
Christophe Corpechot +2 more
doaj +1 more source
Biliary Bicarbonate Secretion Constitutes a Protective Mechanism against Bile Acid-Induced Injury in Man [PDF]
, 2011 Background: Cholangiocytes expose a striking resistance against bile acids: while other cell types, such as hepatocytes, are susceptible to bile acid-induced toxicity and apoptosis already at micromolar concentrations, cholangiocytes are continuously ...
Amelsberg A +21 more
core +1 more source
Farnesoid X receptor prevents hyperuricemia via activating ATP‐binding cassette subfamily G member 2
Rheumatology &Autoimmunity, EarlyView.Farnesoid X receptor (FXR) activation reduces serum uric acid levels by upregulating the intestinal urate transporter ATP‐binding cassette subfamily G member 2 (ABCG2). These findings uncover a novel metabolic pathway for urate excretion and suggest that FXR agonists (e.g., obeticholic acid), represent a promising therapeutic strategy for the treatment
Rui Li +5 more
wiley +1 more source
Regulation of lipid metabolism by obeticholic acid in hyperlipidemic hamsters
Journal of Lipid Research, 2017 The farnesoid X receptor (FXR) plays critical roles in plasma cholesterol metabolism, in particular HDL-cholesterol (HDL-C) homeostasis. Obeticholic acid (OCA) is a FXR agonist being developed for treating various chronic liver diseases. Previous studies
Bin Dong +4 more
doaj +1 more source